Antoni Chan MD (Prof) synovialjoints
1 month 3 weeks ago
In a 17-year real-world psoriasis cohort, patients on IL-17i had 75% lower odds and IL-23i patients had 84% lower odds of developing #PsA vs TNF inhibitors. Is biologic class selection a PsA interception strategy? Prospective controlled trials are needed Abstr#072 @RheumNow https://t.co/jpdZjGK7VV
Mrinalini Dey DrMiniDey
1 month 3 weeks ago
#OP088 at #EULAR2026 found that rare deleterious variants in telomere-related genes were associated with increased RA-ILD risk, independent of MUC5B status. The effect size was similar to that seen in idiopathic pulmonary fibrosis. @RheumNow
Janet Pope Janetbirdope
1 month 3 weeks ago
#Autoimmune #progressive #pulmonary #fibrosis
Large Spanish registry
❎more mortality if not on #DMARDs
?underRx of proven #Rx with #antifibrotics
Median survival post #dx #PPF 7.8 yrs
Can we do better?
#ABST POS0430
@RheumNow #EULAR2026 https://t.co/gP7apxfEPS
sheila RHEUMarampa
1 month 3 weeks ago
Multiparametric renal MRI in LN:
Structural MRI can differentiate bet. active and stable dse
Exudative = active inflamm
In quanti analysis, low ADC values may reflect fibrosis.
A potential non-invasive biomarker?
OP092 @rheumNow #EULAR2026 https://t.co/IarTGOen7v
Aurelie Najm AurelieRheumo
1 month 3 weeks ago
DIPSA RCT: diet in PsA
92 pts 3 arms Mediterranean vs DASH low-calorie vs standard advice
Primary takeaway: amount of weight loss matters more than diet!
-All groups lost modest weight 1–2.5 kg
-All improved similarly in DAPSA -4 to -6 wk 24
-No differences for disease https://t.co/U0cxtdl2Yb
Mrinalini Dey DrMiniDey
1 month 3 weeks ago
#OP0112 at #EULAR2026: Real world RISE registry data shows incr use of semaglutide and tirzepatide across RMDs, particularly RA and PsA. Tirzepatide achieved greater weight loss than semaglutide, with ongoing analyses assessing effects on disease activity and function. @RheumNow
sheila RHEUMarampa
1 month 3 weeks ago
This retrospective cohort of NPSLE pts
showed clinical assocs with MRI findings: Pts w/ focal symptoms - abn MRI
Pts w/ diffuse symptoms - normal MRI except brain atrophy
Interesting to know how this can aid in future mgt strategies for NPSLE
OP093 @RheumNow #EULAR2026 https://t.co/omvdWk6EZK
Aurelie Najm AurelieRheumo
1 month 3 weeks ago
TOGETHER PsA trial
IXE+TIRZEPATIDE TZP vs. IXE alone RCT
Obese or Overweight PsA IR to <3 bioDMARDs
Primary endpoint ≥10% weight & ACR50 wk 36
31.7% IXE+TZP vs. 0.8% for IXE alone
ACR50 IXE+TZP 33.5% & IXE 20.4%, p=0.02)
No clear difference by gender/age/BMI/previous DMARDs https://t.co/zBcfpj2MF6
Mrinalini Dey DrMiniDey
1 month 3 weeks ago
#OP087 explored cancer polygenic risk scores (PRS) in RA. RA was assoc with lower risks of breast and colorectal cancer across all PRS categories, while high prostate cancer PRS may identify RA patients with increased early prostate cancer diagnoses. @RheumNow #EULAR2026 https://t.co/WMqqSFADlW
EULAR – The European Alliance of Associations for Rheumatology – held its 2026 annual Congress in London, where gout was high on the agenda. Current guidelines recommend lifelong urate-lowering therapy (ULT) in a treat-to-target (T2T) strategy to maintain remission, although there is some scope for discussing tapering or discontinuation if remission is achieved.
Aurelie Najm AurelieRheumo
1 month 3 weeks ago
68Ga-RGD PET/CT in PsA reveals large chunk of “silent” synovitis
15 pts 1020 joints
35% affected joints clinically silent
PET signal correlation w/ disease burden:
DAPSA (ρ=0.66)
CRP (ρ=0.69)
Pilot study — not confirmed with US
Needs validation but intriguing signal
#OP068 https://t.co/nhS7PDZN0A
Md Yuzaiful Md Yusof Yuz6Yusof
1 month 3 weeks ago
#EULAR2026 OP077 Another promising CAR-T in autoimmunity. In a Phase II study, Rap-Cel autologous CD19 CAR-T (shorter infusion time ~2d & low dose) vs traditional CAR-T showed drug-free improvement in N=6 #IIM & N=6 #SSc patients. Safety similar to other CAR-Ts @RheumNow https://t.co/byNn5X8JGh
Jiha Lee JihaRheum
1 month 3 weeks ago
Treating inflammation and obesity in PsA with IXEKIZUMAB AND CONCOMITANT TIRZEPATIDE effective with no new safety signals
OP069 @RheumNow #EULAR2026 https://t.co/rkhYvZWpHn
Antoni Chan MD (Prof) synovialjoints
1 month 3 weeks ago
TOGETHER-PsA :ACR50 was already significantly higher with IXE+TZP as early as Week 4 (11.1% vs 3.9%, p=0.029). The metabolic and anti-inflammatory effects of GLP-1/GIP agonism may act synergistically Abstr#069 @RheumNow #EULAR2026 https://t.co/NBQ6CccuCn
1 month 3 weeks ago
TOGETHER PsA trial
IXE+TIRZEPATIDE TZP vs. IXE alone RCT
Obese or Overweight PsA IR to <3 bioDMARDs
Primary endpoint ≥10% weight & ACR50 wk 36
31.7% IXE+TZP vs. 0.8% for IXE alone
ACR50 IXE+TZP 33.5% & IXE 20.4%, p=0.02)
No clear difference by gender/age/BMI/previous DMARDs https://t.co/lFbeb85b9Y
